Tarsus Pharmaceuticals Reaffirmed Full-year 2026 Guidance Of $670M-700M Of Xdemvy Net Product Sales And Peak Sales Potential Exceeding $2B

Benzinga Newsdesk www.benzinga.com Positive 94.2%